Research Directory

Commentary: European IPOs produce surprises

Read more

European biotechs rise in March quarter

Read more

The case for allogeneic cell therapy

Read more

Clinical and market issues for cell-based therapies

Read more

Checkpoint inhibitors - A new horizon for cancer therapy

Read more

Will scanners be the key to translational medicine?

Read more

Why the time has come for MidPharmas

Read more

Alkermes pioneers trial design in depression

Read more

The EU Clinical Trials Regulation: Legislators see light at the end of the tunnel

Read more

Oncology Development Review - 2013: Competition for new cancer treatments intensifies

Read more